JP2025512474A5 - - Google Patents
Info
- Publication number
- JP2025512474A5 JP2025512474A5 JP2024560695A JP2024560695A JP2025512474A5 JP 2025512474 A5 JP2025512474 A5 JP 2025512474A5 JP 2024560695 A JP2024560695 A JP 2024560695A JP 2024560695 A JP2024560695 A JP 2024560695A JP 2025512474 A5 JP2025512474 A5 JP 2025512474A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- acceptable salt
- jak
- heteroarylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263331463P | 2022-04-15 | 2022-04-15 | |
| US63/331,463 | 2022-04-15 | ||
| PCT/US2023/018658 WO2023201044A2 (en) | 2022-04-15 | 2023-04-14 | Jak inhibitor analogs, formulations, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025512474A JP2025512474A (ja) | 2025-04-17 |
| JP2025512474A5 true JP2025512474A5 (enExample) | 2026-04-21 |
Family
ID=88330277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024560695A Pending JP2025512474A (ja) | 2022-04-15 | 2023-04-14 | Ｊａｋ阻害アナログ、製剤、及びそれらの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250257069A1 (enExample) |
| EP (1) | EP4507691A2 (enExample) |
| JP (1) | JP2025512474A (enExample) |
| KR (1) | KR20250003838A (enExample) |
| CN (1) | CN119923257A (enExample) |
| WO (1) | WO2023201044A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3609903A1 (en) * | 2017-05-23 | 2020-02-19 | Theravance Biopharma R&D IP, LLC | Thiocarbamate prodrugs of tofacitinib |
| JP2020520955A (ja) * | 2017-05-23 | 2020-07-16 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | ヤヌスキナーゼ阻害剤のグルクロニドプロドラッグ |
| CA3130349A1 (en) * | 2019-02-28 | 2020-09-03 | Puretech Lyt, Inc. | Lipid prodrugs of jak inhibitors and uses thereof |
-
2023
- 2023-04-14 EP EP23789005.8A patent/EP4507691A2/en active Pending
- 2023-04-14 JP JP2024560695A patent/JP2025512474A/ja active Pending
- 2023-04-14 US US18/856,839 patent/US20250257069A1/en active Pending
- 2023-04-14 CN CN202380040536.3A patent/CN119923257A/zh active Pending
- 2023-04-14 KR KR1020247037966A patent/KR20250003838A/ko active Pending
- 2023-04-14 WO PCT/US2023/018658 patent/WO2023201044A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200700535B (en) | 1, 1a, 5, 5a-tetrahydro-3-thia-cyclopropa[a]pentalenes: tricyclic thiophene derivatives as s1p1/edg1 receptor agonists | |
| JP2011507878A5 (enExample) | ||
| BRPI0714840A2 (pt) | composto, processo para a preparaÇço e uso do mesmo, composiÇço farmacÊutica, processo para a preparaÇço da mesma, e, produto | |
| JP2004531544A5 (enExample) | ||
| RU2005119633A (ru) | Антивирусные нуклеозидные производные | |
| JP2008510828A5 (enExample) | ||
| KR880007460A (ko) | 3-헤테로-치환된-n-벤질-인돌 | |
| KR0139626B1 (ko) | 강심제 | |
| WO2005113537B1 (en) | Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions | |
| JP2004517049A5 (enExample) | ||
| JP2006507355A5 (enExample) | ||
| JP2010501478A5 (enExample) | ||
| JP2022137237A5 (enExample) | ||
| JP2006504738A5 (enExample) | ||
| JP2024545787A5 (enExample) | ||
| JP2008519788A5 (enExample) | ||
| RU2011108485A (ru) | Новые (поли)аминоалкиламиноалкиламидные, алкилмочевинные или алкилсульфонамидные производные эпиподофиллотоксина, способ их получения и их применение в терапии в качестве противораковых средств | |
| CA2567797A1 (en) | Peptidic vasopressin receptor agonists | |
| JP2006513222A5 (enExample) | ||
| JP2007518798A5 (enExample) | ||
| JP2006500372A5 (enExample) | ||
| ES2349622T3 (es) | Benzoilpiridazinas. | |
| JP2007525533A5 (enExample) | ||
| JP2022554330A5 (enExample) | ||
| JP2006524677A5 (enExample) |